Background and Purpose: In this multicentric in silico trial we compared photon, proton, and carbon-ion radiotherapy plans for re-irradiation of patients with squamous cell carcinoma of the head and neck (HNSCC) regarding dose to tumour and doses to surrounding organs at risk (OARs). Material and Methods: Twenty-five HNSCC patients with a second new or recurrent cancer after previous irradiation (70 Gy) were included. Intensity-modulated proton therapy (IMPT) and ion therapy (IMIT) reirradiation plans to a second subsequent dose of 70 Gy were compared to photon therapy delivered with volumetric modulated arc therapy (VMAT). Results: When comparing IMIT and IMPT to VMAT, the mean dose to all investigated 22 OARs was significantly reduced for IMIT and to 15 out of 22 OARs (68%) using IMPT. The maximum dose to 2% volume (D 2 ) of the brainstem and spinal cord were significantly reduced using IMPT and IMIT compared to VMAT. The data are available on www.cancerdata.org. Conclusions: In this ROCOCO in silico trial, a reduction in mean dose to OARs was achieved using particle therapy compared to photons in the re-irradiation of HNSCC. There was a dosimetric benefit favouring carbon-ions above proton therapy. These dose reductions may potentially translate into lower severe complication rates related to the re-irradiation. Squamous cell carcinoma of the head and neck (HNSCC) is the sixth most prevalent cancer in the world and is still considered difficult to cure [1, 2] . In addition to the abuse of alcohol and/or tobacco, infection with human papilloma virus (HPV) is a risk factor.
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Conclusions:
In this ROCOCO in silico trial, a reduction in mean dose to OARs was achieved using particle therapy compared to photons in the re-irradiation of HNSCC. There was a dosimetric benefit favouring carbon-ions above proton therapy. These dose reductions may potentially translate into lower severe complication rates related to the re-irradiation. Squamous cell carcinoma of the head and neck (HNSCC) is the sixth most prevalent cancer in the world and is still considered difficult to cure [1, 2] . In addition to the abuse of alcohol and/or tobacco, infection with human papilloma virus (HPV) is a risk factor.
Despite many new treatment options, the risk of local or regional recurrence for patients with HNSCC having undergone (chemo) radiotherapy or tri-modality treatment is still up to 30% [3] [4] [5] . Additionally, the estimated 5-year cumulative incidence of second new tumours was 13% in the radiotherapy group and 12% in the combined therapy group according to Bernier et al. [6] . The treatment of locoregional recurrence of HNSCC consists of surgical resection with or without adjuvant (chemo)radiation or primary definitive (chemo)radiation, leading to an overall 5-year relative survival rate of 40-66% in selected patients [1] .
In case of an unresectable recurrence, re-irradiation (re-RT) possibly combined with systemic therapy, is an alternative curative option. In the postoperative setting, re-RT should be considered if features in the pathology specimen, such a positive resection margin or extracapsular extension, indicate high risk of recurrence [7] [8] [9] [10] . Long-term disease control and survival can be achieved in patients who receive re-RT as an adjunct to surgical resection. However, the rates of severe grade 3 or 4 toxicity after re-RT are high, with an incidence of approximately 45% at 5 years, and only approximately 1 in 3 patients survives re-RT without recurrence and severe complications [11] . Reduction of the risk of radiationinduced complications and improvement of the oncological outcome are needed [8, [12] [13] [14] 10, 15, 16] .
In recent years, there has been enormous progress in radiotherapy techniques, moving from 3D conformal radiotherapy (3D-CRT) to intensity-modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT), enabling highly conformal treatment with dose reductions to healthy tissue and surrounding organs at risk (OARs) [17, 18] . Still the OARs and healthy tissues frequently receive a significant dose with 3D-CRT and IMRT [18, 19] .
Particle therapy (PT) is becoming increasingly available, which prompts interest among physicians as well as health insurance companies regarding its efficacy in HNSCC. To assess the potential gains of PT for individual patients in the re-irradiation setting, we conducted an in silico treatment planning study on a cohort of 25 HNSCC patients retrospectively retrieved from two Dutch radiotherapy departments. Data are available on www.cancerdata.org [20] .
Methods

Study population
We retrospectively retrieved treatment plans of HNSCC patients stage I to IVB who had undergone (chemo)radiotherapy with curative intent (P50 Gy, including at least lymph node levels II-IV) at Radboud University Medical Centre (UMC) or at MAASTRO clinic and who were subsequently (>1 year later) re-irradiated (with or without surgery and/or chemotherapy), with a relevant overlap of the target volume (clinicaltrial.gov ID: NCT 02242916).
Target volume and OAR definition
An individual neck support and head fixation were used in all patients. For treatment planning purposes, computed tomography (CT) images with intravenous contrast were used. The gross tumour volume (GTV) was delineated as the macroscopic tumour on the planning-CT fused with the hybrid fluorodeoxyglucose positron emission tomography (FDG-PET) and/or after rigid mutualinformation-based registration with magnetic resonance imaging (MRI). The GTV and the clinical target volume (CTV) were delineated using local guidelines (RadboudUMC or MAASTRO clinic) based on Gregoire et al. [21] [22] [23] . The CTV was expanded to the planning target volume (PTV) taking into account the individual institutions' margin recipe: VMAT utilised 4 mm accounting for setup errors, intensity-modulated ion therapy (IMIT) employed 4 mm and intensity-modulated proton therapy (IMPT) 5 mm and 3 mm for the boost to the high risk PTV, to account for both setup and range uncertainties. The low risk volume, PTV with a prescribed dose of 54 Gy (PTV 54Gy ), consisted of the tumour or tumour bed, the pathological lymph nodes and the elective lymph node levels. The high risk PTV planned to a total dose of 70 Gy (PTV 70Gy ) was defined as the tumour or tumour bed and/or pathological lymph nodes. For all 25 patients included in this in silico study, the OARs were outlined by one dosimetrist (M.G.) and supervised by a radiation oncologist (D.E.) for the first and re-RT study set (see Table 1 for the list of OARs). Dental fillings and associated artefacts were delineated and the density was overridden to that of teeth or tissue, respectively, for dental fillings within the treatment beam were an exclusion criterion for PT. The use of any form of bolus to assure an accurate coverage of the target volume was permitted. There was no correction for the use of intravenous contrast.
Treatment planning
The first treatment was considered a precondition in all patients, determining the remaining tolerance dose for the OARs, and therefore not described here. All subsequent paragraphs relate to the re-RT treatment plans. The PTV 54Gy was irradiated to a total dose of 54.25 Gy in 35 fractions of 1.55 Gy, the PTV 70Gy to 70 Gy in 35 fractions of 2 Gy using a simultaneous integrated boost (SIB) technique. In case no elective lymph nodes were included, 70 Gy was prescribed in 35 fractions of 2 Gy to PTV 70Gy (the tumour or pathological lymph node only).
All proton and photon treatment plans were calculated in centres that were already operating and had significant clinical experience in treatment planning. The prescribed dose to the PTV 70Gy was set to 70 Gy of which 99% of the volume had to be covered by 95% of the dose for all modalities in order to enable a direct comparison. All plans were evaluated for robustness.
Dose constraints
For the OARs, the dose limits and priorities were defined in the protocol ( Table 1 ). The dose-volume histograms (DVHs) of the original treatment plans were used to calculate the re-RT constraints for four OARs: the brainstem, spinal cord, mandible and larynx (including arytenoid). Since there was an interval of P1 year between first and second treatment, a 30% recovery was assumed for these four OARs [35] [36] [37] . The locations of the maximum dose (D max ) within an OAR in the first and secondary treatment plans were assumed to be the same, as a worst-case scenario, since the average overlap of the second treatment volume with the first treatment volume was determined to be 67%. No correction for fraction size was performed. Parotid and submandibular glands, if preserved in the first treatment, were attempted to be spared with second and third priority, respectively, without being dose limiting. For larynx, arytenoids and mandible, cumulative dose, which was the sum of the first and second treatment, was considered only dose limiting if the OAR was not part of the CTV in the first and second treatment (see Table 1 ). Attempts were made to minimise dose to the base of tongue, carotid arteries, jugular veins, oral cavity, sternocleidomastoid muscles, swallowing muscles, thyroid and vertebrae, but these structures were not dose limiting. For each re-RT plan, the mean dose (D mean ) was calculated per OAR as well as the near-maximum dose, defined as the highest dose to 2% of the volume (D 2 ), and the near-minimum dose defined as the lowest dose to 98% of the volume (D 98 ) [38] . The mean integral dose (ID) was defined as the mean dose to the imaged part of the patient (body contour) minus CTV, also known as the residual volume at risk (RVR).
Photons
The original clinically applied re-RT treatment plans were created at RadboudUMC using Pinnacle (Pinnacle v8.2g Philips, WI) and at MAASTRO clinic using Varian (Eclipse TM v11.0 Varian Medical Systems, Palo Alto, CA). In order to account for improvements in photon plan techniques over the past years, the actual re-RT photon treatment plans were re-calculated employing state-ofthe-art VMAT planning at MAASTRO clinic. With regard to VMAT, photons were considered to be innately robust relative to PT, therefore no explicit optimisation techniques were incorporated into the VMAT plans as the PTV was assumed to be sufficient to produce a robust plan.
Protons
Proton re-treatment plans were calculated at University of Pennsylvania (UPENN) using IMPT for beam delivery with pencil beam scanning (PBS) (Eclipse TM v11.0 Varian Medical Systems) using beam data modelled for IBA universal nozzle on a gantry (Ion Beam Applications, Louvain-la-Neuve, Belgium) [24] . Multifield optimisation (MFO) was used in the planning process as it produced superior OAR sparing compared to a single field uniform dose (SFO) approach [25] . To preserve small spots, UPENN utilised a universal bolus instead of a more conventional range shifter for the treatment of head and neck tumours [26] . A relative biological effectiveness (RBE) of 1.1 was used [27] . A typical field arrangement consisted of two posterior oblique beams or a posterior and posterior oblique beam, depending on target geometry. A lateral field was added or substituted for one posterior oblique when the D max spinal cord constraint could not be met due to high dose target structures crossing the midline distal to the cord. PT is, with regard to IMPT, known to be intrinsically non-robust, therefore a PTV with a margin of 3 mm from the CTV was created with an additional 2 mm added to the planning optimisation volume to account for range uncertainty. The 5 mm margin is a conservative value for head and neck assuming an overall uncertainty of 3.5% in conversion from Hounsfield Unit (HU) to relative proton stopping power and a range of approximately 15 cm [28, 29] . The following margin definition in head and head-and-neck boost treatments was used: 3 mm transversal to the beam (on account of the residual patient positioning error, robotic table/imager uncertainties and beam steering) and 3 mm along the beam on account of the range uncertainties assuming HU calibration accuracy of 3% and beam range of ca. 10 cm [30, 31] .
Carbon ions
Carbon ion (C-ion) re-RT treatment plans were calculated at University of Marburg using a raster scanning technique with intensity-modulated ion therapy (IMIT) using Syngo PT Planning (Siemens Health Care Systems, Erlangen, Germany), which employed the local effect model (LEM1) for the biologically weighted dose computation [32, 33] . The number of fields varied from 1 (in 1 case) to 3 (in 3 cases).The beam directions (using isocentric table rotations and gantry when deemed advantageous) were chosen individually for each case with two main considerations: avoidance of any unnecessary dose and evading strong density heterogeneities in the beam entrance channels [34] . Furthermore, beam directions traversing patient support and immobilisation devices were avoided. For multiple beam setups reduced the under-dosages caused by potential range uncertainties, a uniform margin of 4 mm was applied with a tolerance of 2 mm, allowing the TPS to place additional raster spots outside the PTV as necessary, thus ensuring target coverage.
Plan robustness evaluation
All treatment plans (VMAT, IMPT, and IMIT) were assessed for robustness of the CTV coverage in their respective centres of origin.
The robustness of the treatment plans was evaluated using worstcase scenario plan calculations with a ± 3 mm isocenter shift in x-, y-, and z-directions combined with a ± 3.5% density shift (12 combinations per plan). The minimal dose to 95% and 98% of the CTV is given (D 95 and D 98 ), respectively.
Storage of imaging datasets
The datasets were stored and exchanged through the secured collaborative MISTIR platform (www.mistir.info) hosted by MAAS-TRO clinic. Quality assurance procedures were applied to assess the necessity of corrections of transformations during treatment planning system (TPS) import and export [39] .
Data evaluation and statistical analysis
Matlab software (The Math Works, Natick, MA) was used for statistical analysis. The dose matrices were scaled to the mean CTV 70Gy doses of 70 Gy (RBE equivalent) as this structure did not change between modalities. The dose metrics were extracted from the plan and statistically compared using two-tailed, signed-rank Wilcoxon tests to determine the significance of pairwise differences compared to VMAT (a p-value of <0.02 was considered significant, taking a Bonferroni correction into account).
Results
Twenty-five cases were included and in total 75 re-RT plans were analysed; one example is illustrated in Fig. 1 . All treatment modalities achieved a comparable dose to the CTV 54Gy and CTV 70Gy ( Table 2 ). All plans were judged to be clinically applicable with worst-case scenario CTV robustness tests resulting in Table I) .
The average scaled values of the D mean and D 2 for the OARs were compared between VMAT and IMPT/IMIT (Table 2, dose significance indicated with an asterisk). When comparing IMIT and IMPT to VMAT, the D mean to all 22 OARs was statistically significantly reduced for IMIT and to 15 out of 22 OARs (68%) using IMPT (p < 0.02). The D 2 for the brainstem and spinal cord was statistically significantly reduced (p < 0.02) using IMPT and IMIT compared to VMAT. The integral dose was highest for VMAT (5.9 Gy), followed by IMPT (3.9 Gy) and IMIT (2.7 Gy). IMPT and IMIT proved to be superior to VMAT in sparing the contralateral located OARs. Depending on the OAR, this dose reduction was up to 85-100% for the contralateral carotid artery and parotid gland, respectively, when using IMPT and 94-99% for the contralateral carotid artery and parotid gland, respectively, when using IMIT. Conversely, IMPT increased the ipsilateral dose to the parotid gland (by 1%), carotid artery (by 2%) and submandibular gland (by 1%), albeit not to a clinically relevant level. The overall average D mean and D 2 for all OARs and each treatment modality were plotted in Fig. 2 , showing that IMIT resulted in a lower D mean in 100% of the cases and IMPT decreased the D mean in 86% of the OARs compared to VMAT. For the D 2 , the respective numbers were 100% and 59%. Dosimetric metrics of selected OARs per patient are plotted in Supplementary Fig. I and II. The maximum dose to the spinal cord (D 2 ), was significantly reduced (Table 2) for most patients using IMPT (96%) and for all patients using IMIT (100%) ( Supplementary  Fig. II) . Regarding D mean to the oral cavity and D 2 of the brainstem, IMIT decreased doses in all cases, compared to 88% and 96% of the cases when delivering IMPT. The D 2 of the Larynx and mandible showed less benefit for IMPT and IMIT (28% and 28%, and 50% and 76%, respectively). For all modalities, radiation doses to the spinal cord and brainstem remained below the constraints without the need to underdose the targets (Supplementary Fig. I ). For the mandible 32% (VMAT), 36% (IMPT) and 28% (IMIT) of patients exceeded the cumulative dose of 120 Gy and the cumulative larynx ] for all OARs is given for volumetric modulated arc therapy (VMAT, blue), intensity-modulated proton therapy (IMPT, red) and intensity-modulated ion therapy (IMIT, green). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) Fig. 3 . Percentage of patients receiving lower dose to the organs at risk when applying IMPT and/or IMIT compared to VMAT. The maximum dose received by 2% of that specific structure (D 2 ) and the mean dose (D mean ) both in Gy(E) are given.
constraint was not met in 78%, 83% and 83% of the patients, respectively.
The number of patients that benefit from IMPT and/or IMIT over VMAT was plotted in Fig. 3 . All individual patients benefitted from IMIT with regard to arytenoid, oral cavity, spinal cord, brain stem and integral dose, as opposed to 80-100% of the patients for IMPT. The D 2 to the bony structures (mandible and vertebrae) decreased in a low percentage of patients using IMPT (28% and 16%) as compared to a high percentage of patients using IMIT (76% and 84%). Overall, in this population of re-irradiated HNSCC patients, PT generated a lower OAR dosage with an advantage of IMIT over IMPT compared to VMAT (84% and 60% respectively).
Discussion
In this ROCOCO in silico clinical trial, through a comparison of state-of-the-art treatment plans prepared according to a strict clinical protocol, we have demonstrated, that re-RT of HNSCC patients using PT (IMPT and IMIT) can result in improved sparing of OAR when compared to photon therapy (VMAT). In most of the cases, this benefit was greater for the IMIT than for IMPT, which could be due to different beam characteristics such as sharper lateral penumbra or different spot size. Whilst the clinical outcome data from randomised trials comparing proton versus carbon ion treatment are not yet available, several treatment planning studies are in line with our findings suggesting advantages of carbon ions in terms of conformity, i.e., dose to the normal tissue [40, 41] .
However, there are confounding factors that may have influenced our findings. In this ROCOCO study, the treatment plans of all the modalities were prepared independently complying with the internal protocols applied in the individual institute's routine clinical practice. Therefore, beyond the contouring and planning goal specifications, the treatment planning procedures themselves were not necessarily alike. As a result, differences may affect the numerical outcome reported here. For instance, the different PTV margins used by the three centres for the different treatment modalities may have caused an underestimation of the value of IMPT for re-irradiating HNSCC for the numerical comparison was unfavourable. These different PTV margins may have arisen from different choices regarding the range uncertainties (see Material and Methods). Even though beyond the scope of this publication a subsequent study with predefined strict margin may shed additional light on this matter.
Also the influence of different beam angles or optimisation criteria cannot be excluded. For carbon ion plans, full beam direction flexibility afforded by the gantry was exploited in the beam setups when deemed advantageous. This decision was taken at the design stage of this in silico trial and had two main reasons. In clinical routine, each of the 10 carbon ion centres currently in operation has some, often (almost) unique, limitations that start to be overcome with additional degrees of freedom by couch roll and/or pitch (www.ptcog.ch). Moreover, there are on-going efforts aiming at making gantries more available. However, research to assess the actual benefit of gantry versus fixed nozzle is warranted.
Should we all change our strategy to carbon ions then in the setting of recurrent HNSCC eligible for radical re-irradiation? We know that there have been many years of experience in using proton beams in daily clinical practice [40, 42] . However, for carbon ion beams there is only little experience, with only three papers describing clinical data on the treatment of HNSCC either as single modality or combined with photons/protons [43] [44] [45] .
In this study, IMPT and IMIT plans using multi-field optimisation and active scanning delivery were investigated owing to their superior delivered dose conformity. Using passive-scattering proton therapy (PSPT) would have altered the results, e.g., Kase et al.
[46] compared PSPT with IMPT in different primary tumour sites including nasal cavity and demonstrated that IMPT resulted in lower doses to OARs. In general, multi-field optimisation offers superior OAR sparing compared with PSPT or pencil beam plans optimised with uniform dose per field, and this benefit can be essential in the context of re-treatment [25, 32] .
Due to the sensitivity of pencil beam scanning proton plans to setup and range uncertainties as well as the degenerate optimal spot map solutions influenced by optimisation algorithms which result in varying degrees of plan robustness, it is critical to examine robustness of PT plans [47] . On the other hand, optimisation algorithms that explicitly incorporate robustness and can reduce uncertainties in IMPT and IMIT plans are likely to lead to less modulated fields, hence resembling SFO approach [48] . The influence of changing anatomy due to tumour regression and weight loss plays a more significant role in PT than in photon therapy which may necessitate the use of more frequent imaging or even adaptive planning strategies [49] [50] [51] [52] [53] . Furthermore, the presence of metal or/and associated artefacts within the treatment beam poses a problem in PT and is argued to be a patient exclusion criterion. Therefore, in our study, these artefacts were delineated and overridden to teeth and water densities, respectively, simulating their absence. This approach carries intrinsic uncertainties, which were assumed to be negligible with respect to influencing key dosimetric parameters. Richard et al. [54] found that in 110 oral cavity/ oropharynx radiation treatment plans artefacts were identified in 74% obscuring the CTV in 95% of these cases. In a constructed head and neck phantom, they measured PTV baseline dose ranges of 98-106% and in the presence of metal amalgam 66-111%. A potential solution may be exchanging metal fillings by composite before proton treatment planning to improve tumour visualisation and dosimetry [54] .
An individualised radiation oncology strategy based on multifactorial decision support systems would be of great help and is currently being developed for different tumour types [55] [56] [57] [58] [59] . In this ROCOCO trial, PT is beneficial for sparing OARs in all HNSCC patients who are candidates for re-RT. However, as long as particle therapy availability is limited and comes at significantly higher costs, finding the patient who is benefitting most is highly relevant to the treating physicians as well as health insurance companies [60] . Therefore, in the prospective Dutch model-based approach, a plan comparison is compulsory for all non-standard indications showing that a reduction in late toxicity computed from a dose difference will actually result in clinically significant lower normal tissue complication probability (NTCP) [62] . This potential benefit, however, must be proven in clinical studies since toxicity is of course dependent on type of tissue, previous dose, interval and co-morbidity (e.g., vascular and metabolic comorbidity). In order to estimate this, a validated NTCP model for re-RT is needed. Developing such a re-RT-NTCP model will be difficult for it has to take into account various additional parameters: e.g., interval between treatments, repair capacity of the tissue as a function of dose given at first treatment and other treatments between radiations, concomitant systemic therapy (not taken into account in the current study).
In summary, the results of this in silico trial have demonstrated that PT can significantly reduce the dose to OARs whilst maintaining the prescription dose (assuming the planned dose is representative of the delivered dose); nevertheless, the exact magnitude of the clinical benefit is uncertain as a decrease in dose does not always translate into a clinically relevant decrease of toxicity risk. Proper development and validation of NTCP models for particle therapy are by no means trivial as there are many uncertainties to contend with, e.g., treatment planning, treatment delivery, relative biological effects, tumour shrinkage, and patient co-morbidities. Rapid-learning approaches along with prospective cohort studies as well as (in silico) randomised controlled trials provide possible solutions in this regard [61] .
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